Treatment

Therapeutic ultrasound for brain disorders

DIAGNOSTIC ULTRASOUND

Ultrasound has been used in medicine since 1951 for diagnostic purposes. In imaging applications, ultrasound is sent to tissues and returns an echo. The recording of the returned echo allows for the creation of ultrasound images. Since the initial development of ultrasound imaging, the principle has remained the same, but systems have improved with advancements in computing power and the arrival of Doppler, 3D imaging, and recently elastography. The power of the ultrasound energy sent to the tissue for imaging is very low in order to not induce any tissue damage.

 

THERAPEUTIC ULTRASOUND

If ultrasound is emitted with a power increased by a factor of 10, it becomes capable of inducing tissue heating that can either activate or destroy the cells. Ultrasound for thermal therapy is called High Intensity Focused Ultrasound (HIFU). In order to not destroy all of the tissues in the path of the ultrasound beam, the ultrasonic waves are emitted by a large aperture transducer and converge at a focal point, where the intensity is 10-1000 times higher than along the path. HIFU is in clinical development for the destruction of tumors throughout the body, including in the prostate, liver, brain, and breast.

The application of HIFU to the brain currently poses a significant problem: the skull limits the passage of ultrasound energy. The skull absorbs about 80% of the emitted energy. In addition, the inhomogeneous nature of the skull leads to a defocusing of the waves and therefore a loss of the focal spot. CarThera® has managed to avoid the problem of the skull bone by using devices that deliver ultrasound energy directly to the brain tissue, without traversing the bone.

  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.